Montelukast for bronchiolitis obliterans syndrome after lung transplantation: A randomized controlled trial

• Published in: PloS one Vol. 13; no. 4; p. e0193564
• Main Authors: Ruttens, David, Verleden, Stijn E, Demeyer, Heleen, Van Raemdonck, Dirk E, Yserbyt, Jonas, Dupont, Lieven J, Vanaudenaerde, Bart M, Vos, Robin, Verleden, Geert M
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 06.04.2018; Public Library of Science (PLoS)
• Subjects: Biology and Life Sciences; Bronchiolitis; Complications and side effects; Dosage and administration; Drug therapy; Lung transplantation; Medicine and Health Sciences; Montelukast; Research and Analysis Methods; Risk factors; Belgium
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0193564

Bronchiolitis obliterans syndrome (BOS) remains the major problem which precludes long-term survival after lung transplantation. Previously, an open label pilot study from our group demonstrated a possible beneficial effect of montelukast in progressive BOS patients with low airway neutrophilia (<15%), and already on azithromycin treatment, in whom the further decline in pulmonary function was attenuated. This was, however, a non-randomized and non-placebo controlled trial. The study design is a single center, prospective, interventional, randomized, double blind, placebo-controlled trial, with a two arm parallel group design and an allocation ratio of 1:1. Randomization to additional montelukast (10 mg/day, n = 15) or placebo (n = 15) was performed from 2010 to 2014 at the University Hospitals Leuven (Leuven, Belgium) in all consecutive patients with late-onset (>2years posttransplant) BOS ≥1. Primary end-point was freedom from graft loss 1 year after randomization; secondary end-points were acute rejection, lymphocytic bronchiolitis, respiratory infection rate; and change in FEV1, airway and systemic inflammation during the study period. Graft loss at 1 y and 2y was similar in both groups (respectively p = 0. 981 and p = 0.230). Montelukast had no effect on lung function decline in the overall cohort. However, in a post-hoc subanalysis of BOS stage 1 patients, montelukast attenuated further decline of FEV1 during the study period, both in absolute (L) (p = 0.008) and % predicted value (p = 0.0180). A linear mixed model confirmed this association. Acute rejection, lymphocytic bronchiolitis, respiratory infections, systemic and airway inflammation were comparable between groups over the study period. This randomized controlled trial showed no additional survival benefit with montelukast compared to placebo, although the study was underpowered. The administration of montelukast was associated with an attenuation of the rate of FEV1 decline, however, only in recipients with late-onset BOS stage 1.